Motion SicknessPhase 3NCT06138613
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
A Phase 3 study testing Tradipitant in people with Motion Sickness, run by Vanda Pharmaceuticals at 1 site in United States.
Trial summary
An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Motion Sickness
- What is being tested?
- Tradipitant
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 705 participants
- Where
- 1 siteUnited States
- Study dates
- 27 Feb 2023to 30 Dec 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- History of Motion Sickness
- Age 18-75
Who cannot join
- Nausea-inducing disorder other than motion sickness
- BMI > 40
- History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists
Trial locations and contacts
1 site in 1 country.
United States1 site
Santa Monica Clinical Trials
Santa Monica, California, 90404
About this study
Official title: Motion Delos: An Open Label Study to Investigate the Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness During Travel
An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
Read the detailed description
This is an open label study to investigate the efficacy and safety of tradipitant in motion sickness affected male and female participants during events historically known to cause motion sickness.
- Conditions
- Motion Sickness
- Being tested
- Tradipitant
- Medical subject headings
- Motion Sickness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TradipitantDrug
Oral Capsule
| Study group | Role | What they receive |
|---|---|---|
| Tradipitant Dose A | Experimental | "See Drug" Receives: Drug: Tradipitant |
| Tradipitant Dose B | Experimental | "See Drug" Receives: Drug: Tradipitant |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and tolerability of tradipitant as measured by reporting of adverse events (AEs).
Safety will be monitored using clinical measures, vital signs, blood chemistry, hematology, urology, and ECGs.
Measured: through study completion, approximately 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2023
- Study start27 Feb 2023
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Motion SicknessStudies of the same condition, open and under way.
- More trials run by Vanda PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 705 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vanda Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06138613
- Sponsor's protocol ID
- VP-VLY-686-3403
- Status last verified
- Nov 2025
- First submitted
- 3 Mar 2023
- Last updated
- 16 Apr 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Motion Delos: An Open Label Study to Investigate the Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness During Travel
- ClinicalTrials.gov ID
- NCT06138613
- Acronym / sponsor ID
- VP-VLY-686-3403
- Conditions
- Motion Sickness
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 705 participants (actual)
- Lead sponsor
- Vanda PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 27 Feb 2023 (actual)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Dec 2027 (estimated)
- First posted
- 18 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
Detailed description
This is an open label study to investigate the efficacy and safety of tradipitant in motion sickness affected male and female participants during events historically known to cause motion sickness.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Tradipitant Dose A | Experimental | Drug: Tradipitant"See Drug" |
| Tradipitant Dose B | Experimental | Drug: Tradipitant"See Drug" |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- History of Motion Sickness
- Age 18-75
Key exclusion criteria (3 listed)
- Nausea-inducing disorder other than motion sickness
- BMI > 40
- History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TradipitantOral Capsule | Drug | Tradipitant Dose A, Tradipitant Dose B |
Primary outcome
Safety and tolerability of tradipitant as measured by reporting of adverse events (AEs).
Time frame: through study completion, approximately 1 year
Safety will be monitored using clinical measures, vital signs, blood chemistry, hematology, urology, and ECGs.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Motion Sickness
Enrolling by invitationObservational study
Virtual Reality Sickness Questionnaire: Psychometrics in Stroke Patients
Motion Sickness
Not yet recruiting
Vagal Auricular Stimulation for Motion Sickness
Chronic Nausea
Recruiting
StableEyes With Active Neurofeedback
Vestibular Disorder, Vestibular Schwannoma
Not yet recruitingObservational study
Motion Sickness Severity and Sensorimotor Performance
Motion Sickness, Somatosensory Disorders
Not yet recruiting
OKT With Gaze and Postural Stabilization on Vertigo, MS and QOL in VBH
Vestibular Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Tradipitant in people with Motion Sickness, run by Vanda Pharmaceuticals at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 16 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and tolerability of tradipitant as measured by reporting of adverse events (AEs). (time frame: through study completion, approximately 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2026.